Here is what you need to know on Thursday, January 28:
The market mood is sour amid concerns about tech earnings, exuberance in stocks, and coronavirus concerns. The Fed's dovish stance failed to cheer investors which now eye US growth figures for the fourth quarter, jobless claims, and vaccine developments.
Gamestop: An army of retail traders buoyed shares of the videogame company, defying hedge funds. The frenzy is seen as a sign of exuberance and a late-stage rally – and is also of worry to regulators and even the White House. Newcomers to markets are mostly organizing on Reddit's wallstreetbets, which has temporarily gone dark.
The Federal Reserve has left its policies unchanged as expected, acknowledging recent weakness and remaining optimistic about a vaccine-fueled recovery in the second half. Fed Chair Jerome Powell stressed that any talk about withdrawing stimulus is "premature" and committed to supporting the economy. Nevertheless, his dovish words failed to cheer investors.
- Federal Reserve Holds Policy Steady; Vaccine crucial to recovery
- Fed Quick Analysis: Powell refuses to stop the stock party, dollar may suffer some pressure
Facebook and Tesla reported results on Wednesday, falling short of investors' expectations. These disappointments added to the sour market mood. The safe-haven US dollar is on the rise.
Stimulus: President Joe Biden's team continues discussing his proposed $1.9 trillion stimulus bill with lawmakers, but is reportedly also ready to go it alone. Treasury Secretary Janet Yellen is involved in deliberations.
The US releases Gross Domestic Product figures for the fourth quarter on Thursday. An annualized increase of 3.9% is projected after sharp changes beforehand. Durable Goods Orders for December mostly missed expectations, somewhat lowering GDP expectations.
US jobless claims are also of interest on Thursday. Applications are set to drop from 900,000 recorded last week, but they remain worrying – especially as the latest figures have shown that the economic misery is spreading beyond pandemic-sensitive sectors.
EUR/USD is on the back foot due to the risk-off mood and also warnings from European Central Bank about the euro's high exchange rate. Officials also opened the door to further lowering the ECB's deposit rate, which stands at -0.50%. Germany and Spain release preliminary inflation figures for January.
The EU and AstraZeneca remain at loggerheads about deliveries of vaccines. The pharmaceutical firm claims that Brussels was late to sign a contract and will, therefore, suffer delays, while the bloc demands immediate deliveries. Regulators are set to approve the jabs on Friday and shortages of doses are already reported in Spain. France is considering new restrictions but has yet to make a decision.
The Pfizer/BioNTech vaccine has proved efficient in neutralizing not only the British variant but also the South African one – albeit with a lower impact on the latter one.
Cryptocurrencies: Bitcoin is trading above $31,000 after dipping earlier below the $30,000 mark. Ethereum is hovering around $1,300.
Gold is on course to close January with a loss, the first such event since 2013.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.